| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.92B | 2.85B | 2.65B | 1.88B | 1.40B |
| Gross Profit | 2.19B | 2.00B | 1.94B | 1.69B | 1.37B |
| EBITDA | 859.49M | 778.78M | 788.82M | 740.17M | 558.83M |
| Net Income | 648.56M | 582.54M | 597.97M | 579.15M | 443.08M |
Balance Sheet | |||||
| Total Assets | 53.04B | 52.52B | 50.85B | 52.89B | 50.88B |
| Cash, Cash Equivalents and Short-Term Investments | 9.98B | 25.26B | 25.18B | 30.06B | 30.47B |
| Total Debt | 4.77B | 4.59B | 4.36B | 4.93B | 2.99B |
| Total Liabilities | 48.47B | 48.62B | 47.13B | 49.76B | 46.44B |
| Stockholders Equity | 4.57B | 3.90B | 3.72B | 3.14B | 4.44B |
Cash Flow | |||||
| Free Cash Flow | 127.33M | 861.76M | 320.21M | 620.08M | 582.44M |
| Operating Cash Flow | 273.98M | 989.53M | 478.85M | 722.58M | 648.29M |
| Investing Cash Flow | -1.60B | -180.88M | -942.75M | -8.28B | -2.53B |
| Financing Cash Flow | -33.09M | 738.33M | -2.88B | 3.00B | 8.17B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $9.73B | 11.86 | 14.05% | 2.31% | 5.87% | 53.36% | |
73 Outperform | $7.92B | 13.16 | 15.83% | 1.97% | 12.63% | 14.25% | |
73 Outperform | $9.73B | 13.92 | 9.02% | 2.43% | 20.72% | 3.63% | |
72 Outperform | $9.16B | 10.32 | 13.39% | 2.97% | 0.12% | 27.30% | |
69 Neutral | $9.12B | 14.56 | 15.16% | 3.05% | 2.85% | 20.57% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
On January 27, 2026, longtime director Dr. Chris Avery notified Cullen/Frost Bankers that he will retire and not stand for re-election when his term expires at the company’s 2026 annual shareholders’ meeting scheduled for April 29, 2026, marking the end of board service that began in 2015 and spanned major initiatives such as organic expansion and the COVID-19 pandemic. On January 28, 2026, the company’s board expanded its size from 13 to 15 members and immediately elected Marsha M. Shields, CEO and managing partner of McCombs Enterprises, and veteran Ernst & Young audit leader Jeffrey M. Rummel as independent directors serving on the Audit and Risk Committees, bolstering Cullen/Frost’s governance with deep Texas business ties and substantial financial, risk and corporate oversight experience that is expected to support the bank’s ongoing growth strategy.
The most recent analyst rating on (CFR) stock is a Hold with a $144.00 price target. To see the full list of analyst forecasts on Cullen/Frost Bankers stock, see the CFR Stock Forecast page.